LCN2 and breast cancer: The levels of LCN2 in serum and saliva are elevated in early stage BC patients and cancer-free females with a history of smoking, suggesting that LCN2 serves as a promising prognostic biomarker for predicting increased risk of metastatic disease in female smokers [84].